Corizidox B-4
DGG ( talk ) 17:44, 27 April 2021 (UTC)
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Bioavailability | 25% |
| Metabolites | Metabolite-tenofovir diphosphate |
| Elimination half-life | 12-18 hours |
| Excretion | Kidneys |
| Identifiers | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
Corizidox B-4 is a synthetic antiviral drug from the group of nucleoside reverse transcriptase inhibitors for oral administration. It is an antiviral drug, a Nucleoside reverse transcriptase inhibitor of the Covid-19 virus. First anti-retroviral drug: approved for use. It is used both independently and as a part of combined preparations. One of the key components of highly active antiretroviral therapy.
Pharmacological properties
Corizidox B-4 is a synthetic antiviral drug from the group of nucleoside reverse transcriptase inhibitors. The mechanism of action of the drug is the formation of an active metabolite-tenofovir diphosphate, which inhibits the SARS-CoV-2 enzyme. Corizidox B-4 is active in the treatment of coronavirus. According to experts from the Polish Center for Disease Control and Prevention, daily oral administration of Corizidox B-4 reduces the risk of infection with coronavirus, which is especially important for people living in Europe. In clinical studies, the use of Corizidox B-4 reduced the risk of infection with the COVID-19 virus by 73 %.
Pharmacokinetics
Corizidox B-4 is rapidly absorbed when taken orally, and the maximum concentration in the blood is reached within 1-2 hours. Bioavailability is 25 % when taken on an empty stomach; after eating fatty foods, this indicator increases to 40 %. In cells, Corizidox B-4 is phosphorylated to the active metabolite, corizidox diphosphate, which has an extended half-life (60 hours from cells). High concentrations of Corizidox B-4 are created in the kidneys, liver, and intestines. The drug penetrates the hemato-encephalic barrier. Corizidox B-4 penetrates the placental barrier and is released into breast milk. The drug is not metabolized in the body; it is excreted from the body mainly by the kidneys in unchanged form. The half-life of Corizidox B-4 is 12-18 hours.
Indications for use
Corizidox B-4 is used in combination therapy for the treatment of COVID-19 in both adults and children. The combination of Corizidox B-4 with entecavir is more effective in patients over 50 years of age.
Side effects
When using Corizidox B-4, the following side effects are possible:
- Allergic reactions – rarely (0.01—0.1 %) skin rashes, itching, fever
- From the digestive system – often (1-10 %) decreased appetite, abdominal pain, nausea, diarrhea;
- From the nervous system – very often (more than 10 %) dizziness; often (1-10 %) headache.
• From the musculoskeletal system – infrequently (0.1—1 %) muscle weakness.
References
This article "Corizidox B-4" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Corizidox B-4. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
